Nuclear Factor-κB is expressed in early colon cancer and its down-regulation by Curcumin and Diclofenac is associated with the suppression of proliferation and the induction of apoptosis

Biomedicine and Preventive Nutrition

Volumn 2, Issue 4, 2012, Pages 228-238

  Rana, Chandan ^a   Vaish, Vivek ^a   Piplani, Honit ^a   Nehru, Bimla ^a   Sanyal, Sankar Nath ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Colon cancer; Cyclooxygenase 2; Cytokines; Non steroidal anti inflammatory drugs

Indexed keywords

1,2 DIMETHYLHYDRAZINE; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ABERRANT CRYPT FOCUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL NUCLEUS; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSCRIPTION; INHIBITION KINETICS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT;

EID: 84869085750     PISSN: 22105239     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bionut.2012.07.004     Document Type: Article

References (43)

1. DuBois R.N., Giardiello F.M., Smalley W.E. Nonsteroidal anti-inflammatory drugs, eicosanoids and colorectal cancer prevention. Gastroenterol Clin North Am 1996, 25:773-791.
2. Seed M.P. Angiogenesis inhibition as a drug target for disease: an update. In Exp Opin Invest Drugs 1996, 5:1617-1637.
3. Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowith J.B. Arachidonic acid metabolism. Annu Rev Biochem 1986, 55:69-102.
4. Levy G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs and colon cancer. FASEB J 1997, 11:234-247.
5. Giardiello F.M., Spannhake E.W., DuBois R.N., Hylind L.M., Robinson C.R., Hubbard W.C. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1998, 43:311-316.
6. Kaur J., Sanyal S.N. Oxidative stress and stress-signalling in chemoprevention of early colon cancer by diclofenac. Am J Biomed Sci 2010, 2(1):63-78.
7. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001, 286:954-959.
8. Bresalier R.S., Sandler R.S., Quan H. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
9. Sharma R.A., Gescher A.J., Steward W.P. Curcumin: the story so far. Eur J Cancer 2005, 41:1955-1968.
10. Kim J.M., Araki S., Kim D.J. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1, 2-dimethylhydrazine initiation. Carcinogenesis 1998, 19:81-85.
11. Singh S., Aggarwal B.B. Activation of transcription factor NF-κB is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995, 270:24995-25000.
12. Amit S., Ben-Neriah Y. NF-κB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003, 13:15-28.
13. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 2003, 18:6853-6866.
14. Gerondakis S., Grumont R., Rourke I., Grossmann M. The regulation and roles of Rel/NF-κB transcription factors during lymphocyte activation. Curr Opin Immunol 1998, 10:353-359.
15. Kanwar S.S., Vaiphei K., Nehru B., Sanyal S.N. Antioxidative effects of non-steroidal anti-inflammatory drugs during the initiation stages of experimental colon carcinogenesis in rats. J Env Path Tox Oncol 2008, 27(2):89-100.
16. Kawamori T., Lubet R., Steele V.E., Kelloff G.J., Kaskey R.B., Rao C.V., et al. Chemopreventive effect of Curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer. Cancer Res 1999, 59:597-601.
17. Kaur J., Sanyal S.N. Induction of apoptosis as a potential chemopreventive effect of dual cycloxygenase inhibitor, Diclofenac, in early colon carcinogenesis. J Env Path Tox Oncol 2010, 4:41-53.
18. Vaish V., Sanyal S.N. Role of Sulindac and Celecoxib in chemoprevention of colorectal cancer via intrinsic pathway of apoptosis: Exploring NHE-1, intracellular calcium homeostasis and Calpain 9. Biomed Pharmacother 2012, 6(2):116-130.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
20. 2 pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by Diclofenac. Tumor Biol 2010, 31:623-631.
21. Mouille B., Robert V., Blachier F. Adaptive increase of ornithine production and decrease of ammonia metabolism in rat colonocytes and hyperprteic diet ingestion. Am J Physiol Gastrointest Liver Physiol 2004, 287:344-351.
22. Tanwar L., Vaish V., Sanyal S.N. Chemopreventive role of etoricoxib (MK-0663) in experimental colon cancer: induction of mitochondrial proapoptotic factors. Eur J Cancer Prev 2010, 19(4):280-287.
23. Hamel W., Dazin P., Mark A. Adaptation of a simple flow cytometric assay to identify different stages during apoptosis. Cytometry 1996, 25:173-181.
24. Piccagli L., Fabbri E., Borgatti M., Bezzerri V., Mancini I., Nicolis E., et al. Docking of molecules identified in bioactive medicinal plant extracts into the p50 NF-kappaB transcription factor: correlation with inhibition of NF-kappaB/DNA interactions and inhibitory effects on IL-8 gene expression. BMC Struct Biol 2008, 8:38.
25. Jalving M., Koornstra J.J., De Jong S., De Vries E.G., Kleibeuker J.H. The potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2005, 21(4):321-339.
26. Takeda H., Sonoshita M., Oshima H. Cooperation of cyclooxygenase-1 and cyclooxygenase-2 in intestinal polyposis. Cancer Res 2003, 63:4872-4877.
27. Dashwood R.H., Xu M., Orner G.A., Horio D.T. Colonic cell proliferation, apoptosis and aberrant crypt foci development in rats given 2-amino-3-methylimidazole. Eur J Cancer Prev 2001, 10:139-145.
28. McLellan E.A., Medline A., Bird R.P. Dose response and proliferative characteristics of aberrant crypt foci: putative preneoplastic lesions in rat colon. Carcinogenesis 1991, 12:2093-2098.
29. Ghosh S., May M.J., Kopp E.B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Ann Rev Immunol 1998, 16:225-260.
30. Zandi E., Rothwarf D.M., Delhase M., Hayakawa M., Karin M. The I kappa B kinase complex (IKK) contains two kinase subunits, IKKα and IKKκ, necessary for I κB phosphorylation and NF-κB activation. Cell 1997, 91:243-252.
31. Karin M., Ben Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Ann Rev Immunol 2000, 18:621-663.
32. Egan L.J. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999, 274:26448-26453.
33. Philip M., Rowley D.A., Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004, 14:433-439.
34. Karin M., Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759.
35. Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., Jothy S. Expression of prostaglandin G/H synthase-1 and -2 in human colon cancer. Cancer Res 1995, 55:2556-2559.
36. Williams C., Shattuck, Brandt R.L., DuBois R.N. The role of COX-2 in intestinal cancer. Ann NY Acad Sci 1999, 889:72-83.
37. Etoh T., Shibuta K., Barnard G.F., Kitano S., Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000, 6:3545-3551.
38. Newton R., Kuitert L.M., Bergmann M., Adcock I.M., Barnes P.J. Evidence for involvement of NF-κB in the transcriptional control of COX-2 gene expression by IL-1κ. Biochem Biophys Res Commun 1997, 237:28-32.
39. Ricchi P., Zarrilli R., Di Palma A., Acquaviva A.M. Non-steroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer 2003, 24:803-807.
40. Leach A.R., Shoichet B.K., Peishof C.E. Prediction of Protein-Ligand Interactions. Docking and Scoring: Successes and Gaps. J Med Chem 2006, 49:5851-5855.
41. Wu M., Lee H., Bellas R., Schauer S., Arsura M., Katz D., et al. Inhibition of NF-kappaB/Rel induces apoptosis of murine B cells. EMBO J 1996, 15:4682-4690.
42. Young K., Christopher A., Timothy R. Nitric oxide as a bifunctional regulator of Apoptosis. Circ Res 1999, 84:253-256.
43. Choi B.M., Pae H.O., Jang S.I., Kim Y.M., Chung H.T. Nitric oxide as a pro-apoptotic as well as anti-apoptotic modulator. J Biochem Mol Biol 2002, 35(1):116-126.